Altimmune, Inc.

As of June 30, 2026, Altimmune, Inc. carries a market capitalization of 519.25M, placing it among publicly traded companies globally. Its enterprise value stands at 265.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Altimmune, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Altimmune, Inc. has 194.47M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12,298.38, and the price-to-book ratio stands at 1.25.

These figures are as of June 30, 2026. The EV/Sales ratio of 9,772.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 265.18M versus a market cap of 519.25M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Altimmune, Inc. maintains a current ratio of 26.78, meaning it holds 26.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.60, indicating elevated leverage, while an interest coverage ratio of -28.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Altimmune, Inc. posted a negative return on equity (ROE) of -28.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.58, reflecting losses generated across the asset base. The company generates approximately 471.90 in revenue per employee across its workforce of 57.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Altimmune, Inc.'s stock has declined approximately 42.35% over the past 52 weeks. The 50-day moving average sits at 2.57, while the 200-day moving average is 2.88.

Over the twelve months ended June 30, 2026, Altimmune, Inc. generated 27,134.30 in revenue and converted that into -80.32M in net income, yielding earnings per share of -0.64. EBITDA reached -87.64M, while operating income came in at -87.73M.

As of June 30, 2026, Altimmune, Inc. holds 285.59M in cash and equivalents against 31.53M in total debt, resulting in a net debt position of -24.74M. Total book value stands at 415.07M, with working capital of 282.12M providing operational flexibility.

Altimmune, Inc. produced -66.97M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -47,266.20 in capital expenditures, free cash flow totaled -67.01M - equivalent to -0.54 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -323,306.45 and net profit margin of -296,000.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -20.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -69.12, meaning Altimmune, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Altimmune, Inc.'s most recent stock split took place on September 14, 2018 with a 30:1 split ratio.

As of June 30, 2026, Altimmune, Inc. has an Altman Z-Score of 4.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.